Dyslipidemia Associated With Type II Diabetes Mellitus
Conditions
Keywords
Dyslipidemia, Type II Diabetes Mellitus
Brief summary
This study investigated the effectiveness of pravastatin on renal function in Korean dyslipidemic patients with Type 2 diabetes.
Detailed description
This survey study investigated the effect of routine initiation single dose of pravastatin (10 mg, 20 mg, or 40 mg) on renal function in Korean dyslipidemic patients with Type 2 diabetes. The study also examined the effect of pravastatin on lipid profiles, glucose metabolism, and safety.
Interventions
DRUGPravastatin
Routine initiation dose was 10 mg, 20 mg or 40 mg single dose once daily. Depending on patient response, dose could have been increased up to 40 mg. Maintenance dose was 10-40 mg once daily.
Sponsors
Daiichi Sankyo Korea Co., Ltd.
Daiichi Sankyo
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Participants with Type 2 diabetes (currently using an antidiabetic drug or satisfying diagnostic criteria of diabetes as defined by American Diabetes Association) * Participants with dyslipidemia (currently using an antidyslipidemic drug or satisfying the Health Insurance Review & Assessment Service insurance coverage treatment criteria\*) for whom drug treatment with pravastatin is confirmed * Participants determined to be eligible as subjects at the discretion of the investigator * Participants who voluntarily provided written consent using the Informed Consent Form on Use of Information
Exclusion criteria
* Participants who had administered pravastatin prior to study participation * Participants with hypersensitivity to the investigational product or its history * Participants with an active liver disease or persistent elevation of transaminase with an unknown cause * Pregnant woman or women with childbearing potential, breastfeeding mothers * Children * Participants with severe hepatic or renal insufficiency * Participants with myopathy * Participants with cholestasis * Participants with hypercholesterolemia due to hyperalphalipoproteinemia accompanied by HDL cholesterol elevation * Participants with a genetic problem such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage Change Rate From Baseline in the Modification of Diet in Renal Disease(MDRD) Estimated Glomerular Filtration Rate (eGFR) at Week 24 After Routine Care of Pravastatin Administration | Week 24 post-dose | The following formula was used to calculate MDRD eGFR: MDRD eGFR (mL/min/1.73 m\^2) = 186 x (serum creatinine) -1.154 x (age)-0.203 x (0.742 if female) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage Change Rate from Baseline in Modification of Diet in Renal Disease (MDRD) Estimated Glomerular Filtration Rate (eGFR) at Week 12 and Week 48 After Routine Care of Pravastatin Administration | Week 12 and Week 48 post-dose | The following formula was used to calculate MDRD eGFR: MDRD eGFR (mL/min/1.73 m\^2) = 186 x (serum creatinine)\^-1.154 x (age)\^-0.203 x (0.742 if female) |
| Change from Baseline in Modification of Diet in Renal Disease (MDRD) Estimated Glomerular Filtration Rate (eGFR) at Week 12 and Week 48 after Routine Care of Pravastatin Administration | Week 12 and Week 48 post-dose | The following formula was used to calculate MDRD eGFR: MDRD eGFR (mL/min/1.73 m\^2) = 186 x (serum creatinine)\^-1.154 x (age)\^-0.203 x (0.742 if female) |
| Percentage Change Rate from Baseline in Estimated Glomerular Filtration Rate (eGFR) using the Chronic Kidney Disease Epidemiology Collaboration(CKD-EPI) Formula at Week 12, Week 24, and Week 48 After Routine Care of Pravastatin Administration | Week 12, Week 24, and Week 48 post-dose | The following formula was used to calculate CKD-EPI eGFR: CKD-EPI eGFR (mL/min/1.73 m\^2) = 141 × min (serum creatinine/k, 1)\^α × max (serum creatinine/k, 1)\^-1.209 × 0.993\^(age) × 1.018 (if female), where k is 0.7 for females and 0.9 for males, α is -0.329 for females and -0.411 for males, min indicates minimum serum creatinine/k or 1, and max indicates maximum serum creatinine/k or 1. |
| Change from Baseline in Estimated Glomerular Filtration Rate (eGFR) using the Chronic Kidney Disease Epidemiology Collaboration(CKD-EPI) Formula at Week 12, Week 24, and Week 48 After Routine Care of Pravastatin Administration | Week 12, Week 24, and Week 48 post-dose | The following formula was used to calculate CKD-EPI eGFR: CKD-EPI eGFR (mL/min/1.73 m\^2) = 141 × min (serum creatinine/k, 1)\^α × max (serum creatinine/k, 1)\^-1.209 × 0.993\^(age) × 1.018 (if female), where k is 0.7 for females and 0.9 for males, α is -0.329 for females and -0.411 for males, min indicates minimum serum creatinine/k or 1, and max indicates maximum serum creatinine/k or 1. |
| Change from Baseline in Modification of Diet in Renal Disease (MDRD) Estimated Glomerular Filtration Rate (eGFR) at Week 24 After Routine Care of Pravastatin Administration | Week 24 post-dose | The following formula was used to calculate MDRD eGFR: MDRD eGFR (mL/min/1.73 m\^2) = 186 x (serum creatinine)\^-1.154 x (age)\^-0.203 x (0.742 if female) |
| Change from Baseline in Total Cholesterol, Low Density Lipoprotein Cholesterol, High Density Lipoprotein-Cholesterol, Triglycerides, Fasting Plasma Glucose at Week 12, Week 24, and Week 48 After Routine Care of Pravastatin Administration | Week 12, Week 24, and Week 48 post-dose | Blood plasma samples will be collected to assess lipids (total cholesterol \[mg/dL\], low density lipoprotein cholesterol (LDL-C) \[mg/dL\], high density lipoprotein-cholesterol (HDL-C) \[mg/dL\], triglyceride \[mg/dL\], and fasting plasma glucose \[mg/dL\]). |
| Percentage Change Rate from Baseline in Hemoglobin A1c (HbA1c) at Week 12, Week 24 and Week 48 After Routine Care of Pravastatin Administration | Week 12, Week 24, and Week 48 post-dose | Blood plasma samples will be collected to assess hemoglobin A1c (HbA1c) (%)levels. |
| Change from Baseline in Hemoglobin A1c (HbA1c) at Week 12, Week 24 and Week 48 After Routine Care of Pravastatin Administration | Week 12, Week 24, and Week 48 post-dose | Blood plasma samples will be collected to assess hemoglobin A1c (HbA1c) (%)levels. |
| Number of Participants With Treatment-emergent Adverse Events After Routine Care of Prevastatin Administration | Week 48 post-dose | Treatment-emergent adverse event (TEAE) is defined as an event that emerges during treatment, having been absent pretreatment, or worsens relative to the pretreatment state. |
| Percentage Change Rate from Baseline in Total Cholesterol, Low Density Lipoprotein Cholesterol, High Density Lipoprotein-Cholesterol, Triglycerides, Fasting Plasma Glucose at Week 12, Week 24, and Week 48 After Routine Care of Pravastatin Administration | Week 12, Week 24, and Week 48 post-dose | Blood plasma samples will be collected to assess lipids (total cholesterol \[mg/dL\], low density lipoprotein cholesterol (LDL-C) \[mg/dL\], high density lipoprotein-cholesterol (HDL-C) \[mg/dL\], triglyceride \[mg/dL\], and fasting plasma glucose \[mg/dL\]). |
Countries
South Korea
Outcome results
None listed